The George Washington University School of Medicine, Washington, DC, U.S.A.
The Department of Veteran Affairs Medical Center, Washington, DC, U.S.A.
Anticancer Res. 2019 Aug;39(8):4333-4335. doi: 10.21873/anticanres.13600.
Secondary malignancies are relatively common and clinically important phenomena following both chemotherapy and radiotherapy. The majority of these cases are acute leukemias, the occurrence of which have been thoroughly documented and studied. More rarely, chronic myeloid leukemias (CML) may arise subsequent to treatment of a primary malignancy. Literature review on such developments following treatment of Hodgkin's Lymphoma (HL) is scant. Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.
继发恶性肿瘤是化疗和放疗后相对常见且具有重要临床意义的现象。这些病例多数为急性白血病，其发生已得到充分的记录和研究。更罕见的是，慢性髓性白血病（CML）可能在治疗原发性恶性肿瘤后出现。关于霍奇金淋巴瘤（HL）治疗后发生此类疾病的文献回顾很少。在此，作者报告了 3 例在开始治疗霍奇金淋巴瘤（HL）后 5 年内诊断出的 CML 病例；其中 1 例患者的 CML 具有罕见突变的非典型变异型，伴有 BCR-JAK2 融合。
